Former Chairman of NHS Improvement Ed Smith Joins Advisory Board at Cognetivity Neurosciences
Ed Smith brings experience in a range of top advisory roles across the UK’s public and private healthcare sectors
VANCOUVER, BC, May 19, 2021 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) today announced the appointment of Ed Smith to its advisory board with immediate effect.
Ed has had considerable experience in top roles within the UK’s publicly-funded healthcare system, the National Health Service (NHS). He is the former Chairman of NHS Improvement and Deputy Chairman of NHS England, two of the most significant bodies overseeing patient care in the NHS, which together receive the majority of the Department of Health and Social Care’s core annual budget of around £160 billion.
He remains involved in the NHS as Independent Chair of Birmingham Health Partners, a strategic alliance between the University of Birmingham and two NHS Foundation Trusts that is dedicated to applying healthcare innovations in clinical care.
Additionally, Ed has held many senior positions within the private healthcare sector, currently sitting as Chairman of the Advisory Board at HCA Healthcare UK, the UK’s largest provider of privately-funded healthcare. Its parent company, HCA Healthcare, is the largest private healthcare provider in the world, operating around 200 hospitals and 2,000 sites of care across the UK and US.
He is also an Independent Non-Executive Director at the video consultation provider Push Doctor – which offers services to 6 million NHS patients – as well as Chairman of Assura PLC, the UK’s leading real estate investment trust (REIT) for primary care medical centres.
Prior to assuming his portfolio of healthcare roles, Ed spent 30 years at PricewaterhouseCoopers (PwC) in a variety of top UK and international roles, including Strategy Chairman and Global Assurance Chief Operating Officer. Beyond the world of healthcare, he is Senior Independent Director and Chair of the Audit Committee of HS2 Ltd, which is developing the UK’s new High Speed Two (HS2) rail network, a project with a budget of roughly £100 billion.
“We’re thrilled to welcome Ed to the company,” said Dr Sina Habibi, Cognetivity’s CEO. “He has served with distinction in two of the most important bodies involved in running the NHS, and is sure to provide us with invaluable insight as we continue to gain traction in the UK and other key healthcare markets.”
“Of course, he also has extensive experience on the private-sector side, giving him a valuable breadth of perspective on the needs of both buyers and sellers. Most of all, he has a clear passion for improving health and social care – he shares our values and aspirations deeply, and will be a natural fit.”
Ed also expressed his pleasure at the announcement. “I’m delighted to be joining Cognetivity’s advisory board,” he said. “I believe the company’s unique approach to diagnosing early-stage dementia can make an enormous difference to our global flight against the scourge of the disease.”
“What they are doing has huge potential to save and improve lives. I look forward greatly to working with the team and providing what input and guidance I can to see their technology deployed throughout UK health systems and beyond.”
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain to support diagnosis of dementia. It has achieved regulatory approval for clinical use in the UK and Europe with future clinical approval anticipated in North America and elsewhere in the world.
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Cognetivity Neurosciences Ltd
For further information: For media enquiries, please contact: Josh Stanbury, email@example.com, 416-628-7441